A Randomized Study Comparing Venetoclax and Azacitidine to

Enrolling By Invitation

18 years - 99 years

All

Phase 2

1 Location

Brief description of study

This research is being done to see how an investigational combination of study drugs works in comparison to chemotherapy in people with acute myeloid leukemia. This study involves the following study drug combinations. You will only receive one of these combinations: • Venetoclax and azacitidine (investigational combination) • Cytarabine and idarubicin or daunorubicin (per standard of care) • Liposomal daunorubicin and cytarabine (per standard of care)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Acute Myeloid Leukemia
Age: 18 years - 99 years
Gender: All

Male or Female, Age 18 or older, Acute Myeloid Leukemia

Updated on 04 Aug 2024. Study ID: 850133

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

A Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

Brief description of study

Eligibility of study